Cite
Ozaki Y, Aoyama Y, Masuda J, et al. Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study. BMC Cancer. 2022;22(1):36doi: 10.1186/s12885-021-09128-1.
Ozaki, Y., Aoyama, Y., Masuda, J., Inagaki, L., Kawai, S., Shibayama, T., Maeda, T., Kurata, M., Yoshida, K., Saeki, S., Hosonaga, M., Fukada, I., Hara, F., Kobayashi, T., Kobayashi, K., Miyake, S., Takano, T., Ueno, T., & Ohno, S. (2022). Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study. BMC cancer, 22(1), 36. https://doi.org/10.1186/s12885-021-09128-1
Ozaki, Yukinori, et al. "Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study." BMC cancer vol. 22,1 (2022): 36. doi: https://doi.org/10.1186/s12885-021-09128-1
Ozaki Y, Aoyama Y, Masuda J, Inagaki L, Kawai S, Shibayama T, Maeda T, Kurata M, Yoshida K, Saeki S, Hosonaga M, Fukada I, Hara F, Kobayashi T, Kobayashi K, Miyake S, Takano T, Ueno T, Ohno S. Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study. BMC Cancer. 2022 Jan 04;22(1):36. doi: 10.1186/s12885-021-09128-1. PMID: 34983437; PMCID: PMC8728947.
Copy
Download .nbib